8
项与 重组带状疱疹疫苗(CHO细胞)(成都迈科康生物) 相关的临床试验 / Active, not recruiting临床3期 随机、双盲评价生产规模下连续三批重组带状疱疹疫苗(CHO细胞)在40周岁及以上人群中接种后的免疫原性批间一致性的Ⅲ期临床试验
主要目的:
评价商业化规模下生产的连续三批次重组带状疱疹疫苗(CHO细胞)按0,2月各1剂免疫程序接种于40周岁及以上人群后,在抗-gE抗体几何平均浓度(Geometric Mean Concentration, GMC)方面的批间一致性。
次要目的: 评价商业化规模下生产的连续三批次重组带状疱疹疫苗(CHO细胞)按0,2月各1剂免疫程序接种于40周岁及以上人群后,在抗-gE抗体阳转率方面的批间一致性;
评价商业化规模生产的重组带状疱疹疫苗(CHO细胞)按0,2月各1剂免疫程序接种于40周岁及以上人群的安全性。
A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced At a Commercial Scale in Subjects Aged 40 Years and Older.
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
/ Active, not recruiting临床3期 A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
100 项与 重组带状疱疹疫苗(CHO细胞)(成都迈科康生物) 相关的临床结果
100 项与 重组带状疱疹疫苗(CHO细胞)(成都迈科康生物) 相关的转化医学
100 项与 重组带状疱疹疫苗(CHO细胞)(成都迈科康生物) 相关的专利(医药)
100 项与 重组带状疱疹疫苗(CHO细胞)(成都迈科康生物) 相关的药物交易